longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

300401

300401
----

LongbridgeAI

GARDEN BIOPHARMA: Subsidiary obtains drug registration certificate

Zhitong
Aug 25, 2025 at 08:13 AM

GARDEN BIOPHARMA announced that its wholly-owned subsidiary, Zhejiang Garden Pharmaceutical Co., Ltd., has received the "Drug Registration Certificate" approved and issued by the National Medical Products Administration for "Alpha-Lipoic Acid Tablets" and "Bisoprolol Amlodipine Tablets." Alpha-Lipoic Acid Tablets are mainly used for the treatment of diabetic peripheral neuropathy, while Bisoprolol Amlodipine Tablets are primarily used for the treatment of hypertension. The acquisition of the drug registration certificates will further enrich the company's product line, promote the upgrade of product capabilities, and have a positive impact on the company's development

Source: Zhitong The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.

GARDEN BIOPHARMA

GARDEN BIOPHARMA

300401.SZ

Open

--

High

--

Low

--

Prev Close

--

P/ETTM

--

Market Cap

--